55
Participants
Start Date
December 31, 2016
Primary Completion Date
November 30, 2017
Study Completion Date
January 31, 2018
Sorafenib
Sorafenib will be administrated at a dose of 400 mg twice daily (consisting of two 200-mg tablets).Treatment interruptions and up to two dose reductions (first to 400 mg once daily and then to 400 mg every 2 days) will permitted for drug- related adverse effects. If further dose reductions will required, patients will withdraw from the study
Best Supportive care
Liver Support, pain management
El Kahraba Hosital, Cairo
Ain Shams University Hospital, Cairo
Nasser Institute, Cairo
Ain Shams University
OTHER